Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6200
Peer-review started: May 25, 2023
First decision: June 15, 2023
Revised: July 24, 2023
Accepted: August 18, 2023
Article in press: August 18, 2023
Published online: September 16, 2023
Mixed-phenotype acute leukemia (MPAL) is characterized by acute undifferentiated leukemia with blasts co-expressing myeloid and lymphoid antigens. However, consensus regarding the ideal management strategy for MPAL is yet to be established, owing to its rarity.
A 55-year-old male was diagnosed with T/myeloid MPAL. Vincristine, pred
CR was maintained in a patient with MPAL who underwent haploidentical peripheral blood stem-cell transplantation after additional venetoclax/decitabine cycles.
Core Tip: We report a 55-year-old male diagnosed with T/myeloid mixed-phenotype acute leukemia (MPAL) who received induction chemotherapy with vincristine, prednisolone, daunorubicin, and L-asparaginase. The patient experienced septic shock 10 days post-induction therapy and received antibiotic therapy to treat extended-spectrum beta-lactamase-positive bacteremia. Bone marrow examination post-sepsis recovery revealed refractory disease. To reduce the infection risk, venetoclax and decitabine were administered as chemotherapy-free induction therapy. After two additional venetoclax/decitabine cycles, the patient underwent haploidentical peripheral blood stem-cell transplantation, subsequently achieving complete response. This is the third report documenting the successful treatment of refractory T/myeloid MPAL with venetoclax and a hypomethylating agent.